Inadequate prescription of chronic consumption of proton pump inhibitors in a hospital in Mexico. Cross-sectional study

Revista Espanola de Enfermedades Digestivas

Volumn 105, Issue 3, 2013, Pages 131-137

  Sánchez Cuén, Jaime Alberto ^a   Irineo Cabrales, Ana Bertha ^a   Bernal Magaña, Gregorio ^a   Peraza Garay, Felipe de Jesús ^b  

^a Department of Gastroenterology   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SINALOA   (Mexico)

Author keywords

Chronic consumption; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CHRONIC GASTRITIS; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DIAGNOSTIC ERROR; DYSPEPSIA; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HUMAN; INAPPROPRIATE PRESCRIBING; INTESTINE METAPLASIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEXICO; OBSERVATIONAL STUDY; OUTPATIENT; POLYPHARMACY; POPULATION RESEARCH; PRESCRIPTION; SELF MEDICATION; STOMACH ULCER; HOSPITAL; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MEXICO; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS;

EID: 84879641859     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082013000300003     Document Type: Article

References (38)

1. Forgacs I, Loganayagan A. Overprescribing proton pump inhibitors. BMJ 2008;336:2-3.
2. Cienfuegos Alfredo. Series: from physiology to the clinic: Gastric secretion and proton pump inhibitors. Rev Col Gastroenterol 2010;25:94-98.
3. National Prescribing Service. Proton pump inhibitors. Citado en http://www.nps.org.au/__data/assets/pdf_file/0012/111423/clinical_guidance_final_PPI.pdf
4. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-3122.
5. Noguerado Asensio A, Rodríguez Barrientos R, Zelaya Castro P, Sánchez Sempere A, Antuña Blanco F, Lutz García E, et al. Use of acid-suppressive medications in hospitalized patients. An Med Interna 2002;19:557-560.
6. Ponce Romero M, Berenguer Lapuerta J. Indicaciones actuales de los inhibidores de la bomba de protones. Rev Clin Esp 2003;203:136-138.
7. Garrigues V, Bastida G, I. Bau, Ponce J. Gastroesophageal reflux with normal endoscopy. What can be done? Rev Sdad Valenciana Patol Dig 2000;19:141-151.
8. DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:190-200.
9. Elsevier Doyma, S.L. Grupo de trabajo de la guía de práctica clínica sobre ERGE. Manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Guía de Práctica Clínica. Actualización 2007. Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2007. Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 1. Barcelona, marzo 2007.
10. Sobrino-Cossío S, López-Alvarenga JC, Remes-Troche JM, Galvis-García ES, Soto-Pérez JC, Teramoto-Matsubara O, et al. Proton pump inhibitors in gastroesophageal reflux disease: "a custom-tailored therapeutic regimen". Rev Esp Enferm Dig 2012;104:367-378.
11. Martín de Argila, de Prados C. Security of proton pump inhibitors. Rev Esp Enferm Dig 2011;103:98.
12. Martínez M JD, Henao R SC. Consumo crónico de medicamentos inhibidores de la bomba de protones (IBP) y el desarrollo de gastritis atrófica corporal. Rev Col Gastroenterol 2007;22(PT. 4):302-307.
13. Doweck J. Adverse effects of proton pump inhibitors. Acta Gastroen-terol Latinoam 2009:39:219-222.
14. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80-87.
15. Niklasson A, Lindström L, Simrén M, Lindberg G, Björnsson E. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010;105:1531-1537.
16. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009;104(SUPL. 2):S2-S4.
17. Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L, Thein H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton) 2006;11:381-385.
18. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;14;167:950-955.
19. de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk-Lafeber AB, Siersema PD et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther 2012;36:941-949.
20. Sagar M, Janczewska I, Ljungdahl A, Bertilsson L, Seensalu R. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther 1999; b13:453-458.
21. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-1121.
22. Oh S. Proton pump inhibitors uncommon adverse effects. Aust Fam Physician 2011;40:705-708.
23. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuk-er JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-1348.
24. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010;103:387-395.
25. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010;56:112-116.
26. Raña Garibay R. Efectos adversos y falla a los inhibidores de la bom-ba de protones (IBP). Rev Gastroenterol Méx 2011;76(SUPL.1): 49-52.
27. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504-508.
28. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol 2009;104 (SUPL. 2): 21-26.
29. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-2056.
30. Linney S, Fernandes T, Einarson T, Sengar A, Walker JH, Mills A. Association Between Use of Proton Pump Inhibitors and a Clostridium difficile-Associated Disease Outbreak: Case-Control Study. Can J Hosp Pharm 2010;63:31-37.
31. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001;13:611-616.
32. Labenz J, Petersen KU, Rösch W, Koelz HR. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantopra-zole. Aliment Pharmacol Ther 2003;17:1015-1019.
33. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001;23:116-117.
34. de Burgos Lunar C, Novo del Castillo S, Llorente Díaz E, Salinero Fort M A. Study of prescription-indication of proton pump inhibitors. Rev Clin Esp 2006;206:266-270.
35. Martín-Echevarría E, Pereira Juliá A, Torralba M, Arriola Pereda G, Martín Dávila P, Mateos J, et al. Assessing the use of proton pump inhibitors in an internal medicine department. Rev Esp Enferm Dig 2008;100:76-81.
36. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007;83:66-68.
37. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol 2010;69:543-552.
38. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen NM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol 2010 66:1265-1267.